- Home
- AIRT vs CNTB Comparison
AIRT vs CNTB Comparison
Compare AIRT & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- CNTB
- Stock Information
- Founded
- AIRT 1980
- CNTB 2012
- Country
- AIRT United States
- CNTB United States
- Employees
- AIRT N/A
- CNTB N/A
- Industry
- AIRT Air Freight/Delivery Services
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- CNTB Health Care
- Exchange
- AIRT Nasdaq
- CNTB Nasdaq
- Market Cap
- AIRT 59.0M
- CNTB 54.4M
- IPO Year
- AIRT N/A
- CNTB 2021
- Fundamental
- Price
- AIRT $23.51
- CNTB $2.00
- Analyst Decision
- AIRT
- CNTB Strong Buy
- Analyst Count
- AIRT 0
- CNTB 2
- Target Price
- AIRT N/A
- CNTB $7.50
- AVG Volume (30 Days)
- AIRT 4.4K
- CNTB 259.0K
- Earning Date
- AIRT 08-13-2025
- CNTB 09-04-2025
- Dividend Yield
- AIRT N/A
- CNTB N/A
- EPS Growth
- AIRT N/A
- CNTB N/A
- EPS
- AIRT N/A
- CNTB N/A
- Revenue
- AIRT $291,850,000.00
- CNTB $26,033,000.00
- Revenue This Year
- AIRT N/A
- CNTB N/A
- Revenue Next Year
- AIRT N/A
- CNTB N/A
- P/E Ratio
- AIRT N/A
- CNTB N/A
- Revenue Growth
- AIRT 1.75
- CNTB N/A
- 52 Week Low
- AIRT $14.56
- CNTB $0.51
- 52 Week High
- AIRT $26.70
- CNTB $2.86
- Technical
- Relative Strength Index (RSI)
- AIRT 52.88
- CNTB 54.68
- Support Level
- AIRT $22.06
- CNTB $1.79
- Resistance Level
- AIRT $24.50
- CNTB $2.45
- Average True Range (ATR)
- AIRT 1.01
- CNTB 0.35
- MACD
- AIRT 0.01
- CNTB 0.02
- Stochastic Oscillator
- AIRT 27.26
- CNTB 37.29
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.